home / stock / bysi / bysi news

BYSI News and Press, BeyondSpring Inc. From 10/12/20

Stock Information
Company Name: BeyondSpring Inc.
Stock Symbol: BYSI
Market: NASDAQ
Website: beyondspringpharma.com
Menu
BYSI BYSI Quote BYSI Short BYSI News BYSI Articles BYSI Message Board
Get BYSI Alerts

News, Short Squeeze, Breakout and More Instantly...
BYSI - BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans

NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology and chemotherapy-induced neutropenia therapies, announc...
BYSI - BeyondSpring's manuscript on Plinabulin published in JAMA Oncology

JAMA Oncology, the American Medical Association’s peer-reviewedjournal published  BeyondSpring's ([[BYSI]] -0.3%) manuscript, titled 'Efficacy of Plinabulin vs. Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell ...

BYSI - JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy

NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology therapies to transform the lives of patients with unmet me...

BYSI - Akero Continues Efruxifermin Trial, And Other News: The Good, Bad And Ugly Of Biopharma

Akero Therapeutics to continue with mid stage Efruxifermin trial. BioMarin initiated mid stage study for BMN 307. BeyondSpring presents positive data for Plinabulin in preventing neutropenia. For further details see: Akero Continues Efruxifermin Trial, And Other News: Th...
BYSI - Additional data show BeyondSpring' plinabulin at par with Amgen' pegfilgrastim

BeyondSpring ([[BYSI]] -0.6%) has announced new data on its lead drug plinabulin, demonstrating it to be a favorable option for preventing chemo-induced neutropenia ((CIN)) during the pandemic, compared to Amgen's Neulasta (pegfilgrastim, Peg), long-lasting G-CSF.In terms of severe ...

BYSI - New Data Highlights BeyondSpring's Plinabulin as a Highly Effective Agent for Preventing Chemotherapy-Induced Neutropenia, with Potential to Reduce Clinical Resources for COVID-19

NEW YORK, Sept. 24, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc . (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology therapies to transform the lives of patients with unmet m...

BYSI - New CFO for BeyondSpring

BeyondSpring (BYSI) has appointed Elizabeth Czerepak as Chief Financial Officer, effective immediately. The company's subsidiary, Seed Therapeutics has appointed Edward Liu as Chief Financial Officer. Mr. Liu will also retain his responsibilities as CFO of BeyondSpring, China. Ms. Czerep...
BYSI - BeyondSpring Appoints Elizabeth Czerepak as Chief Financial Officer

NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Following its recent receipt of two Breakthrough Therapy Designations in both the U.S. and China for Plinabulin in the chemotherapy-induced neutropenia (CIN) indication, BeyondSpring Inc. (the “Company” or “BeyondSpri...

BYSI - BeyondSpring to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020

NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet med...

BYSI - BeyondSpring nabs accelerated review in U.S. and China for its lead asset Plinabulin

BeyondSpring (NASDAQ: BYSI )   +9.5%  in premarket as the FDA and China’s Center for Drug Evaluation  designates the company's Plinabulin as a Breakthrough Therapy for the treatment of chemotherapy-induced neutropenia (CIN). More news on: BeyondSpring...
Previous 10 Next 10